Rachel R Kroe-Barrett

List of Publications by Year
in descending order

24 papers	680 citations	687363 13 h-index	642732 23 g-index
24 all docs	24 docs citations	24 times ranked	1221 citing authors

#	Article	IF	Citations
1	Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs, 2015, 7, 778-791.	5.2	92
2	Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics. Analytical Biochemistry, 2016, 508, 78-96.	2.4	92
3	Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies. MAbs, 2017, 9, 1143-1154.	5.2	69
4	Competing aggregation pathways for monoclonal antibodies. FEBS Letters, 2014, 588, 936-941.	2.8	64
5	IgG Charge: Practical and Biological Implications. Antibodies, 2019, 8, 24.	2.5	54
6	IgG cooperativity â€“ Is there allostery? Implications for antibody functions and therapeutic antibody development. MAbs, 2017, 9, 1231-1252.	5.2	52
7	Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies. Biochemical and Biophysical Research Communications, 2018, 504, 19-24.	2.1	37
8	Weak protein interactions and pH- and temperature-dependent aggregation of human Fc1. MAbs, 2015, 7, 1072-1083.	5.2	32
9	Weak IgG selfâ€•and heteroâ€association characterized by fluorescence analytical ultracentrifugation. Protein Science, 2018, 27, 1334-1348.	7.6	27
10	VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis. MAbs, 2020, 12, 1709322.	5.2	24
11	Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn. MAbs, 2017, 9, 1105-1117.	5.2	22
12	Biophysical Techniques for Characterizing the Higher Order Structure and Interactions of Monoclonal Antibodies. ACS Symposium Series, 2015, , 285-327.	0.5	21
13	Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms. Journal of Visualized Experiments, 2017, , .	0.3	17
14	Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Molecular Cancer Therapeutics, 2021, 20, 96-108.	4.1	15
15	Efficient Qualitative and Quantitative Determination of Antigen-induced Immune Responses. Journal of Biological Chemistry, 2016, 291, 16361-16374.	3.4	13
16	A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway. Molecular Cancer Therapeutics, 2021, 20, 2250-2261.	4.1	11
17	Fully human antibodies against the Protease-Activated Receptor-2 (PAR-2) with anti-inflammatory activity. Human Antibodies, 2011, 20, 83-94.	1.5	7
18	Dataset of the binding kinetic rate constants of anti-PCSK9 antibodies obtained using the Biacore T100, ProteOn XPR36, Octet RED384, and IBIS MX96 biosensor platforms. Data in Brief, 2016, 8, 1173-1183.	1.0	7

#	Article	IF	Citations
19	Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5). MAbs, 2019, 11, 956-964.	5.2	7
20	An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases. International Journal of Pharmaceutics, 2021, 609, 121162.	5.2	6
21	Optimizing NBE PK/PD assays using the Gyrolab Affinity Software; conveniently within the bioanalyst's existing workflow. Bioanalysis, 2018, 10, 397-406.	1.5	4
22	Non-neutralizing antibodies increase endogenous circulating Ang1 levels. MAbs, 2018, 10, 1260-1268.	5.2	4
23	Xâ€ray crystal structure localizes the mechanism of inhibition of an <scp>ILâ€36R</scp> antagonist monoclonal antibody to interaction with Ig1 and Ig2 extra cellular domains. Protein Science, 2020, 29, 1679-1686.	7.6	3
24	Effect of the ADCC-Modulating Mutations and the Selection of Human IgG Isotypes on Physicochemical Properties of Fc. Journal of Pharmaceutical Sciences, 2022, 111, 2411-2421.	3.3	0